Axitinib

Active ingredient: Axitinib

In short: Axitinib tablets in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Axitinib tablets in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC.

Forms & strengths•1 mg tablets of axitinib: red, film-coated, oval tablets, debossed with "Pfizer" on one side and "1 XNB" on the other side. •5 mg tablets of axitinib: red, film-coated, triangular tablets, debossed with "Pfizer" on one side and "5 XNB" on the other side.
LabelPrasco Laboratories
Label updatedNov 16, 2026

What is Axitinib used for?

Axitinib tablets in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Axitinib tablets in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC.

Axitinib tablets as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.

Axitinib dosage

First-Line Advanced RCC

Axitinib tablets in Combination with Avelumab

The recommended starting dosage of axitinib tablets is 5 mg orally taken twice daily (12 hours apart) with or without food in combination with avelumab 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. When axitinib tablets are used in combination with avelumab, dose escalation of axitinib tablets above the initial 5 mg dose may be considered at intervals of two weeks or longer. Review the Full Prescribing Information for recommended avelumab dosing information.

Axitinib tablets in Combination with Pembrolizumab

The recommended starting dosage of axitinib tablets is 5 mg orally twice daily (12 hours apart) with or without food in combination with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes until disease progression or unacceptable toxicity. When axitinib tablets are used in combination with pembrolizumab, dose escalation of axitinib tablets above the initial 5 mg dose may be considered at intervals of six weeks or longer. Review the Full Prescribing Information for recommended pembrolizumab dosing information.

Second-Line Advanced RCC

When axitinib tablets are used as a single agent, the recommended starting oral dose is 5 mg twice daily. Administer axitinib tablet doses approximately 12 hours apart with or without food.

Important Administration Instructions

Advise patients to swallow axitinib tablets whole with a full glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. Advise the patient to take the next prescribed dose at the usual time.

Dose increase or reduction is recommended based on individual safety and tolerability.

Recommended axitinib tablet dosage increases and reductions are provided in Table 1.

Over the course of treatment, patients who tolerate axitinib tablets for at least two consecutive weeks with no adverse reactions Grade >2 (according to the Common Toxicity Criteria for Adverse Events [CTCAE]), are normotensive, and are not receiving anti-hypertension medication, may have their dose increased.

Dose Modification | Dose Regimen

Recommended starting dosage | 5 mg twice daily

Dosage increase

First dose increase | 7 mg twice daily

Second dose increase | 10 mg twice daily

Dosage reduction

for management of adverse drug reactions

First dose reductionfrom 5 mg twice daily | 3 mg twice daily

Second dose reduction | 2 mg twice daily

Recommended dosage modifications for adverse reactions for axitinib tablets are provided in Table 2. …

How to take Axitinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypertension

Advise patients that hypertension may develop during axitinib tablet treatment and that blood pressure should be monitored regularly during treatment .

Arterial/Venous Thromboembolic Events

Advise patients that arterial and venous thromboembolic events have been observed during axitinib tablet treatment and to inform their doctor if they experience symptoms suggestive of thromboembolic events .

Hemorrhage

Advise patients that axitinib tablets may increase the risk of bleeding and to promptly inform their doctor of any bleeding episodes .

Cardiac Failure

Advise patients that cardiac failure may develop during axitinib tablet treatment and that signs or symptoms of cardiac failure should be regularly monitored for during treatment . …

Warnings & precautions

Do not take this medicine if: None.

In a controlled clinical study with axitinib for the treatment of patients with RCC, hypertension was reported in 145/359 patients (40%) receiving axitinib and 103/355 patients (29%) receiving sorafenib. Grade 3/4 hypertension was observed in 56/359 patients (16%) receiving axitinib and 39/355 patients (11%) receiving sorafenib. Hypertensive crisis was reported in 2/359 patients (<1%) receiving axitinib and none of the patients receiving sorafenib. The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of axitinib treatment and blood pressure increases have been observed as early as 4 days after starting axitinib. Hypertension was managed with standard anti-hypertensive therapy. Discontinuation of axitinib treatment due to hypertension occurred in 1/359 patients (<1%) receiving axitinib and none of the patients receiving sorafenib .

Ensure that blood pressure is well-controlled prior to initiating axitinib tablets. Monitor patients for hypertension and treat as needed with standard anti-hypertensive therapy. Withhold and then dose reduce axitinib tablets or permanently discontinue based on severity of hypertension .

In clinical trials, arterial thromboembolic events have been reported, including deaths. In a controlled clinical study with axitinib for the treatment of patients with RCC, Grade 3/4 arterial thromboembolic events were reported in 4/359 patients (1%) receiving axitinib and 4/355 patients (1%) receiving sorafenib. Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving axitinib and none of the patients receiving sorafenib .

Axitinib tablets have not been studied in patients who had an arterial thromboembolic event within the previous 12 months. …

Axitinib side effects

The following clinically significant adverse reactions are discussed elsewhere in the labeling :

•Hypertension

•Arterial thromboembolic events

•Venous thromboembolic events

•Hemorrhage

•Cardiac failure

•Gastrointestinal perforation and fistula formation

•Thyroid dysfunction

•Reversible posterior leukoencephalopathy syndrome

•Proteinuria

•Hepatotoxicity

•Hepatic impairment

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of axitinib has been evaluated in combination with avelumab in JAVELIN Renal 101 and pembrolizumab in KEYNOTE-426 for the first-line treatment of patients with advanced RCC . The data described reflect exposure to axitinib in combination with avelumab in 434 patients and pembrolizumab in 429 patients .

The safety of axitinib has been evaluated in 715 patients in second-line monotherapy studies, which included 537 patients with advanced RCC. The data described reflect exposure to axitinib in 359 patients with advanced RCC who participated in a randomized clinical study versus sorafenib .

First-Line Advanced RCC

Axitinib in Combination with Avelumab

The safety of axitinib in combination with avelumab was evaluated in JAVELIN Renal 101. …

Drug interactions

Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. Co-administration of axitinib tablets with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5 inhibitor must be co-administered, the axitinib tablet dose should be reduced .

Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. Co-administration of axitinib tablets with strong CYP3A4/5 inducers (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, and St. John's wort) should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 induction potential is recommended . Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.

About this medicine

Axitinib is a kinase inhibitor. Axitinib has the chemical name N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide. The molecular formula is C22H18N4OS and the molecular weight is 386.47 Daltons. The chemical structure is:

Axitinib is a white to light-yellow powder with a pKa of 4.8. The solubility of axitinib in aqueous media over the range pH 1.1 to pH 7.8 is in excess of 0.2 µg/mL. The partition coefficient (n-octanol/water) is 3.5.

Axitinib tablets are supplied as red, film-coated tablets containing either 1 mg or 5 mg of axitinib together with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and Opadry® II red 32K15441 as inactive ingredients. The Opadry II red 32K15441 film coating contains lactose monohydrate, HPMC 2910/Hypromellose 15cP, titanium dioxide, triacetin (glycerol triacetate), and red iron oxide.

How it works: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8134c0da-9985-461e-85f4-d33709233535. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate